DNAtrix is a clinical stage biotechnology company specializing in virus-driven immunotherapies for cancer treatment. Their lead product, DNX-2401, is a modified common cold virus that targets and selectively kills cancer cells. DNAtrix's innovative platform technology utilizes the unique characteristics of viruses to create a portfolio of powerful therapies for hard-to-treat cancers that have shown resistance to conventional treatments.

Their pipeline includes DNX-2401 (tasadenoturev) and DNX-2440, both of which have demonstrated the ability to selectively kill tumor cells and stimulate long-term anti-tumor immune responses. DNX-2401, in particular, is being evaluated as a potential treatment for highly aggressive brain tumors and has shown promising results in extending the survival of patients with recurrent glioblastoma. It has received several notable designations and approvals from regulatory agencies, highlighting its potential.

DNAtrix is also developing DNX-2440, a next-generation immunotherapy encoding human OX40 ligand, which has shown significant anti-cancer activity in preclinical studies. With a focus on expanding their pipeline of cancer immunotherapies, DNAtrix continues to harness the power of oncolytic viruses to combat cancer effectively